Background and objective: COPD is a complex condition with a heavy burden of disease. Many multidimensional tools have been studied for their prognostic utility but none has been universally adopted as each has its own limitations. We hypothesize that a multidimensional tool examining four domains, health-related quality of life, disease severity, systemic effects of disease and patient factors, would better categorize and prognosticate these patients. 
INTRODUCTION
COPD is one of the leading causes of morbidity and mortality worldwide, with further increases in its prevalence and mortality to be expected in the coming years.
1,2 Its complexity and burden of disease are well recognized by pulmonologists and has led to the introduction of the multidimensional Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification system in 2011 (GOLD 2011) which provides recommendations for a more holistic approach towards the management of COPD. 3, 4 The complexity of this disease is further underlined by the numerous multidimensional tools that have been studied to help in its prognostication. Studies carried out on GOLD 2011 have not shown that it has better prognostic utility compared with GOLD 2007, and have also generated conflicting results when outcomes in the GOLD Groups B and C were compared.
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SUMMARY AT A GLANCE
The BMI, airflow obstruction, St George's Respiratory Questionnaire and age (BOSA) index is a new tool, built and prospectively validated in this study for prognosticating patients with COPD. It predicts mortality moderately well and is at least equivalent to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 in Asian patients. It has the potential to be used widely as complex testing or equipment is not required.
recent pooled analysis of existing COPD studies by Soriano et al. affirmed that GOLD 2007 and GOLD 2011 did not differ significantly in their prognostic utility. 11 It also demonstrated that patients in GOLD Group D had the worst mortality with a risk 3.5 times that of their GOLD Group A counterparts whilst patients in GOLD Groups B and C had similar mortality risk which are 1.7-2.2 times that of patients in GOLD Group A. 11 Other tools that have demonstrated prognostic utility include the St George's Respiratory Questionnaire (SGRQ), the modified Medical Research Council (mMRC) Dyspnoea Scale, the BMI, Obstruction, Dyspnoea and Exercise (BODE) index and the COPD comorbidity index (COTE). 6, [12] [13] [14] [15] However, no tool is perfect as can be seen in studies demonstrating that even with low mMRC or BODE index scores patients can still suffer from impairment of health-related quality of life as measured by the SGRQ. 16, 17 Whilst most of these tools have been validated for use in patients with COPD, none have been universally adopted given that no system is perfect and they have their own limitations.
We therefore aimed to build a multidimensional model which accounts for health-related quality of life, disease severity, systemic effects of the disease and patient factors, and which may be used to predict mortality in patients with COPD. We then validated this model in a second cohort of patients.
METHODS

Study design and patients
This is a prospective cohort study of all patients with COPD who were managed in our university hospital between March 2008 and March 2013. This study was run in tandem with another study looking at the prognostic utility of the GOLD 2011 in Asian patients with COPD. 18 We diagnosed COPD in patients with dyspnoea, chronic cough and/or sputum production, with at least 10 pack-years of smoking, and persistent airflow limitation as evidenced by a post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio of less than 0.7. 3 Trained COPD nurses entered the following data into the institutional Central Clinical Research Database: age, gender, height, weight, BMI and when clinically stable in the outpatient setting spirometry results according to the American Thoracic Society guidelines. 19 Primary outcome was that of all-cause mortality. We obtained ethical approval from the National Health Group Domain Specific Review Board.
Model building
We selected variables in the first 300 patients who were recruited: age, gender, BMI, race, SGRQ total score and FEV1 measured as a percentage of the predicted value for consideration in the building of the prediction model. These variables were selected as they have been demonstrated in previous studies to have impact on mortality. 12, 13, [20] [21] [22] [23] Differences in these variables between survivors and non-survivors are presented in Table 1 .
Stepwise logistic regression analysis was then applied to determine the association with mortality of each potential variable. Based on the stepwise logistic regression analysis, the four variables identified to have strongest association were BMI (OR: 0.98, P = 0.043), FEV1 (%, OR: 0.96, P = 0.001), SGRQ (OR: 1.02, P = 0.001) and age (OR: 1.07, P = 0.001) (Nagelkerke R 2 = 0.18, P = 0.001). They were integrated to form the BMI, airflow obstruction, St George's Respiratory Questionnaire and age (BOSA) index (Table 2) . BMI has been demonstrated to have a non-linear inverse relationship with survival, and with an inflection point of 21 shown in previous studies. 12, 20 Age, airflow obstruction and SGRQ have also been demonstrated to be associated with mortality.
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Validation of the BOSA index
The BOSA index was validated prospectively in a second cohort of 772 patients. BMI was allocated a point of either 0 or 1 due to its non-linear relation with survival while the other three variables were sub-classified into quartiles and could be allocated point ranging from 0 to 3. FEV1 quartiles were based on GOLD spirometry classification. 3 Total BOSA scores were obtained as per Table 2 with a minimum score of 0 and a maximum score of 10 obtainable.
Statistical analysis
We classified patients into their respective BOSA quartile groups (Group 1: BOSA score 0-3; Group 2: BOSA score 4-5; Group 3: BOSA score 6; Group 4: BOSA score 7-10). We expressed categorical data as frequency and/or percentage and parametric data as mean AE SD. We compared groups using the chi-square test and analysis of variance (ANOVA), and applied the Bonferroni correction where appropriate. We performed survival analyses to determine if any significant differences in mortality were present between groups. We first used Kaplan-Meier analysis and the log rank test, expressing results as mean AE SEM. We then used Cox regression to adjust for possible confounding variables (i.e. race and gender), with data expressed as hazard ratio (HR) and 95% CI. The adjusted predictive scores for mortality for receiver operator characteristic (ROC) analysis were obtained using logistic regression. We compared the resultant area under the curve (AUC) using a method described by Hanley and McNeil. 24 We used SPSS Statistics 20.0 (IBM, New York, USA) and considered P < 0.05 to be statistically significant.
RESULTS
Patients were followed up for a median of 4.07 years with those in BOSA Group 1 for a mean of 3.22 AE 1.50 years, Group 2 for 3.48 AE 1.42 years, Group 3 for 3.87 AE 1.37 years and Group 4 for 4.06 AE 1.18 years. A total of 772 patients were in the validation cohort of whom 230 (29.8%) were in BOSA Group 1, 298 (38.6%) in Group 2, 104 (13.5%) in Group 3 and 140 (18.1%) in Group 4. Chinese made up 76.6% of the cohort while 17.1% were Malays, 4.9% were Indians and 1.4% were of other ethnicities. There were significant differences in age, BMI, FEV1 and SGRQ amongst the four BOSA groups (Table 3 , P = 0.001, ANOVA).
Patients in Groups 3 and 4 had significantly shorter time to mortality (3.83 AE 0.16 and 3.82 AE 0.13 years, respectively) when compared with their counterparts in Groups 1 (4.45 AE 0.07 years) and 2 (4.21 AE 0.08 years, P < 0.001, log rank test) (Fig. 1) . After adjustment for confounders on Cox regression, time to mortality remained shorter in Group 4 than in Group 1 (HR: 0.29, 95% CI: 0.16-0.51, P < 0.001) and Group 2 (HR: 0.53, 95% CI: 0.34-0.82, P = 0.005), and was similar when compared with Group 3 (HR: 0.94, 95% CI: 0.57-1.55, P = 0.808). The effects of race (P = 0.582) and gender (P = 0.415) were not significant.
The predictive utility for mortality for the BOSA index (AUC: 0.690, 95% CI: 0.640-0.740) was at least equivalent to that of the GOLD 2011 classification system (AUC: 0.64, 95% CI: 0.592-0.691, P = 0.17, ROC comparator) (Fig. 2) . The sensitivity, specificity and predictive values of each BOSA group for mortality are shown in Table 4 .
DISCUSSION
COPD is a chronic and complex condition with a heavy burden of disease. 25 Its complexity can be underscored by the development of numerous tools for use in its prognostication. [5] [6] [7] [8] [9] [10] [12] [13] [14] 16, 21, 24 We have developed the BOSA index which is a simple tool that can be easily used in the outpatient clinical setting, and have validated its use by demonstrating that it has at least similar prognostic utility as the GOLD 2011 classification. Our findings demonstrated that risk of mortality increases with worse BOSA grades, and that race and gender did not affect mortality.
The BOSA index does not require the patient to undergo additional testing such as the 6-min walk test as in the BODE index. The BOSA index encompasses four domains that can reflect prognosis -disease severity, systemic effect of disease, health-related quality of life and patient factors. The obstruction component allows for the severity of airflow obstruction to be measured and studies have demonstrated that risk of mortality increases as FEV1 decreases. 21, 22 BMI reflects the systemic effect of COPD and patients with lower BMI have been shown to be at higher risk of mortality. 20, 26, 27 SGRQ is a fixed-format self-complete questionnaire for measuring health in chronic airflow limitation by examining its effects on symptoms, activities and impacts on daily life. 28 Domingo-Salvany et al. demonstrated that health-related quality of life measures can be used to prognosticate mortality in COPD as patients with worse SGRQ were found to have higher mortality. 13 This prompted us to consider the use of SGRQ rather than mMRC in this model. Age was used to reflect patient factor and has been shown to be associated with worse outcomes in the Third National Health and Nutrition Examination Survey follow-up study with patients in their 80s being at higher risk of 11.6 times for mortality as compared with their counterparts in their 50s. 23 This could be explained by more co-morbidities as well as relatively poorer lung function in the more elderly population.
This study demonstrated that patients in the more severe groups (i.e. Groups 3 and 4) had worse outcomes. There is a clear division in terms of outcomes between patients in Groups 1 and 2 vis-à-vis those in Groups 3 and 4. This is not surprising as a higher BOSA score would suggest a more elderly and thinner patient with poorer lung function who is experiencing greater health status impairment. These are all portents of poorer outcomes.
The BOSA index has moderate prognostic utility and it has at least equivalent prognostic utility as the GOLD 2011 system which is also a multidimensional grading system that is based on airflow obstruction, symptom measurements (i.e. mMRC or COPD assessment test (CAT)) and exacerbation history. We postulate that this may be a result of the BOSA index being better at picking up health impairment compared with GOLD 2011 in our setting where we relied on mMRC rather than on CAT to rate dyspnoea level. 16, 29, 30 Jones et al. and more recently Nonato et al. have also shown that even with zero or low mMRC scores or BODE index scores patients experienced significant health status impairment as measured by SGRQ. 16, 17 This is essential as we postulate that greater health status impairment and increased dyspnoea has important prognostic utility as they not only reflect the severity of the disease and associated complication of sarcopaenia from reduced mobility but also complications from other co-morbidities. 31 Further, the BMI component of the BOSA index will enable the systemic effect of COPD to be measured with studies showing that lower BMI is associated with higher mortality. 20, 26, 27 The moderate predictive utility of the BOSA index is also in keeping with recent studies looking at the use of other multidimensional tools for This study has several strengths. We followed up a cohort of patients with COPD over a 5-year period and prospectively recorded all data to build the model and subsequently to validate it. We also recorded other data such as exacerbation history 1 year prior to entry to study and mMRC scores to facilitate the GOLD 2011 classification. We used the national electronic medical record system which enabled us to retrieve clinical records pertaining to each patient's attendance at the emergency departments and/or admissions to all public hospitals in Singapore. This study also has several weaknesses. We were unable to obtain records of attendances or admissions to private hospitals. This is, however, rare in our setting and should not have an impact on our findings. Data on other co-morbidities and the exact causes of death were also not available. There were concerns if the SGRQ is too troublesome for use in the outpatient clinical settings. However, in our experience, patients typically completed the SGRQ in 10-20 min. They were handed the questionnaires by COPD nurses upon registration at the clinic and utilized the waiting time to complete the questionnaires prior to seeing their respective physicians. Our study size, whilst similar to the BODE index study, is smaller than that of the COTE study. This study could benefit further from a larger study size with more patients in the more severe group (i.e. BOSA Groups 3 and 4) to achieve a more balanced distribution. Nevertheless, this could be a reflection of the actual proportion of patients with the different levels of severity in our clinical setting. Further, the patients in the more severe groups (BOSA Groups 3 and 4) had longer follow-up time compared with their counterparts in the less severe groups and this could potentially have an impact on the mortality data. Finally, our study population appears lean and male-predominant when compared with other studies carried out on the Caucasian populations. These observations are, however, in keeping with the known findings that Asians tend to have lower BMI of up to 3-4 units compared with their Caucasian counterparts and that a higher proportion of smokers in Asia are males. [32] [33] [34] Furthermore, issue of under-diagnosis of COPD amongst females is a known phenomenon. 35, 36 In conclusion, the BOSA index has moderate prognostic utility. It is a simple tool that can be easily applied in the outpatient setting to prognosticate patients. As the BOSA index does not require complex equipment or testing, it has the potential to be used widely. Further studies can be performed to examine its utility in monitoring treatment or health outcomes. Nonetheless, given that the BOSA index has at least similar predictive utility as GOLD 2011 and that it also measures more domains (i.e. health-related quality of life, disease severity, systemic effects of the disease and patient factors) that are known to have impact on mortality, we suggest that it is appropriate to use the BOSA index for prognostication. 
